Market Place
Sourcing Support
Aridis Provides Corporate Update
24 Jun 2024 //
GLOBENEWSWIRE
Aridis Announces Adjournment of Meeting of Stockholders until January 12, 2024
15 Dec 2023 //
GLOBENEWSWIRE
Aridis Announces Third Quarter 2023 Financial Results and Business Update
03 Nov 2023 //
GLOBENEWSWIRE
Aridis Pharmaceuticals Announces $2 Million Offering
02 Aug 2023 //
GLOBENEWSWIRE
Aridis to delist from Nasdaq; Bicycle closes $200M+ offering
18 Jul 2023 //
ENDPTS
Aridis Receives Agreement from EMA on the Study Design & Phase 3 Study of AR-301
17 Jul 2023 //
GLOBENEWSWIRE
Aridis Pharma Shares Rise 33% After FDA Product Designation for AR-301
12 Jul 2023 //
MARKETWATCH
Aridis AR-301 Antibody is Among First Biologics to Receive FDAs QIDP Designation
12 Jul 2023 //
GLOBENEWSWIRE
Aridis Pharmaceuticals` AR-301 Eligible for Consideration under FDA™s Limited
20 Jun 2023 //
GLOBENEWSWIRE
Aridis Receives Agreement from the FDA on Phase 3 Study of AR-301
31 May 2023 //
GLOBENEWSWIRE
Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-Q
25 May 2023 //
GLOBENEWSWIRE
Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-K
26 Apr 2023 //
GLOBENEWSWIRE
Aridis lays off 20% after AstraZeneca ends pneumonia collab
03 Apr 2023 //
FIERCE BIOTECH
Aridis Provides Corporate Update
31 Mar 2023 //
GLOBENEWSWIRE
AZ pulls pneumonia collab with Aridis over allegations of a missed payment
30 Mar 2023 //
FIERCE BIOTECH
Aridis Announces $2.28 Million Registered Direct Offering of Common Stock
14 Mar 2023 //
GLOBENEWSWIRE
Aridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501
13 Mar 2023 //
GLOBENEWSWIRE
Miss for Aridis as antibody flunks phase 3 pneumonia trial
26 Jan 2023 //
FIERCE BIOTECH
Aridis Reports Top-Line Results of the Phase 3 Double-Blinded
25 Jan 2023 //
GLOBENEWSWIRE
New Approaches to Treating Cystic Fibrosis - AR 501 Phase 2 Trial Update
17 Jan 2023 //
GLOBENEWSWIRE
Aridis Pharmaceuticals to Discuss Topline Data from Phase 3 Study of AR-301
28 Dec 2022 //
BIOSPACE
Aridis Pharma Receives Equity Investment from the Cystic Fibrosis Foundation
12 Dec 2022 //
GLOBENEWSWIRE
Aridis Pharma Receives Equity Investment from the Cystic Fibrosis Foundation
12 Dec 2022 //
GLOBENEWSWIRE
Aridis Signs Exclusive Terms to Secure Worldwide Commercial Licenses Pan-Ebol
05 Dec 2022 //
GLOBENEWSWIRE
Aridis Announces a Key Milestone of Closing of Patient the Ph2a Study of AR-501
30 Nov 2022 //
GLOBENEWSWIRE
Aridis Announces Third Quarter 2022 Financial Results and Business Update
21 Nov 2022 //
GLOBENEWSWIRE
Aridis Pharmaceuticals Announces Withdrawal of Public Offering of Common Stock
27 Sep 2022 //
PRNEWSWIRE
Aridis Pharmaceuticals Announces Proposed Public Offering of Common Stock
26 Sep 2022 //
BENZINGA
Aridis Pharma Announces Q2 2022 Financial Results and Business Update
16 Aug 2022 //
PRNEWSWIRE
Aridis Pharmaceuticals Announces First Quarter 2022 Financial Results
16 May 2022 //
PRNEWSWIRE
Aridis Pharmaceuticals Announces 2021 Q4 and Year-End Financial Results
31 Mar 2022 //
PRNEWSWIRE
Aridis Pharmaceuticals CEO Discusses Monoclonal Antibody Cocktail Protection
21 Dec 2021 //
YAHOO
Aridis` CEO Discusses mAb Cocktail Protection Against COVID-19 Omicron Variant
21 Dec 2021 //
PRNEWSWIRE
Aridis Pharmaceuticals Announces Third Quarter 2021 Results
10 Nov 2021 //
PRNEWSWIRE
Aridis Pharmaceuticals Announces Second Quarter 2021 Results
12 Aug 2021 //
PRNEWSWIRE
Aridis COVID mAb Ranks Top 5 Most Potent COVID-19 mAbs Evaluated by the CoVIC
26 Jul 2021 //
PRNEWSWIRE
Aridis Pharma Announces Exclusive License of Suvratoxumab from AstraZeneca
19 Jul 2021 //
PR NEWSWIRE
Aridis Pharmaceuticals COVID mAb AR-712 Neutralizes SARS-CoV-2 Delta Variant
12 Jul 2021 //
PRNEWSWIRE
Aridis Provides Multiple Program Updates Including of a 2ND Inhaled
23 Feb 2021 //
PRNEWSWIRE
Aridis CEO on why the pandemic hasn`t bolstered antibiotics R&D
13 Jan 2021 //
FIERCEBIOTECH
Aridis to Host Fireside Chat with Analysts to Discuss 2021 Outlook
24 Nov 2020 //
PRNEWSWIRE
Aridis Pharmaceuticals EPS misses by $0.02
20 Nov 2020 //
SEEKING ALPHA
Aridis Pharmaceuticals Announces Third Quarter 2020 Results
20 Nov 2020 //
PRNNEWSWIRE
Aridis to Present at the ROTH Capital Healthcare Event "COVID-19 Therapeutics
28 Oct 2020 //
PRNEWSWIRE
Aridis to Present at the ROTH Capital Partners 2020 MedTech
26 Oct 2020 //
PRNEWSWIRE
Aridis Reports Positive Preclinical Efficacy Data of a Highly Effective
19 Oct 2020 //
PRNEWSWIRE
Aridis Pharmaceuticals Announces $8.5 Million Registered Direct Offering
14 Oct 2020 //
PRNEWSWIRE
Aridis Announces Agreement with the FDA on Updated Phase 2 Clinical Trial Design
08 Sep 2020 //
PRNEWSWIRE
Aridis Pharmaceuticals to Participate in Cantor Fitzgerald Virtual Symposium
26 Jun 2020 //
PRNEWSWIRE
Aridis Reports AR-501 Clinical Data: Positive Safety Data a Ph1/2a Trial
22 Jun 2020 //
PRNEWSWIRE
Aridis Pharmaceuticals to Discuss APEXâ„¢ in Virtual Fireside Chat
18 Jun 2020 //
PR NEWSWIRE
